Who backs Bambusa Therapeutics?
11 investors| Investor | Type |
|---|---|
| RA Capital Management | Asset manager |
| The Invus Group | PE / buyout |
| INCE Capital | Venture capital |
| Redmile Group | PE / buyout |
| Salvia (Holzkirchen) | Family office |
| ADAR1 Capital Management | Hedge fund |
| Athos (Family Office) | — |
| BVF Partners | — |
| Dawn Biopharma | — |
| Janus Henderson Investors | — |
| + 1 more investors · a free account shows the complete list | |
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns
Membership and data by Private Market View
Bambusa Therapeutics investors
11 investors are on record for Bambusa Therapeutics, including RA Capital Management, The Invus Group, INCE Capital and Redmile Group. The Series A2 in Oct 2025 drew 9 investors.
Free account
More of Bambusa Therapeutics with a free account
- ·The complete investor list: 11 names
- ·Watch Bambusa Therapeutics: the Monday email on marks, rounds and moves
For fundraisers
Work this list, don’t just read it
These 11 firms already write checks for companies like Bambusa Therapeutics in drug discovery. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.
Membership and data by Private Market View